Artificial Intelligence has become impactful during the last few years in the life sciences, pushing the scientific boundaries forward as exemplified by the recent success of AlphaFold2. In this talk I will provide an overview of how AI has impacted drug design in the last few years, where we are now and what progress we can reasonably expect in the coming years. The presentation will have a focus on deep learning based molecular de novo design, however, also aspects of using multi-agent systems and the integration of AI with automation will be covered.
